RINDOPEPIMUT Anti-EGFRvIII Peptide Vaccine Oncolytic

Drugs of the Future

Volumn 38, Issue 3, 2013, Pages 147-155

  Gedeon, Patrick C ^a,b   Choi, Bryan D ^a,b   Sampson, John H ^a,b,c   Bigner, Darell D ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Biomedical Engineering ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CDX 110; Chemotherapy; Glioblastoma; Malignant brain tumors; Radiotherapy; Rindopepimut

Indexed keywords

ANTIHISTAMINIC AGENT; BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L8A4; MONOCLONAL ANTIBODY Y10; RINDOPEPIMUT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ALLERGIC REACTION; ARTICLE; AUTOIMMUNITY; BRAIN STEM GLIOMA; BRAIN STEM TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKOENCEPHALOPATHY; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 84930538587     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.03.1933992     Document Type: Article

References (41)

1. Dolecek, T.A., Propp, J.M., Stroup, N.E., Kruchko, C. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009. Neuro-oncology 2012, 14(Suppl. 5): v1-v49.
2. Louis, D.N., Ohgaki, H., Wiestler, O.D. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2): 97-109. (Pubitemid 47103521)
3. Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O.D., Zanella, F., Reulen, H.J., Group, A.L.-G.S. Fluorescence-guided surgery with 5- aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7(5): 392-401.
4. Walker, M.D., Strike, T.A., Sheline, G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979, 5(10): 1725-31. (Pubitemid 10187518)
5. Stupp, R., Mason, W.P., van den Bent, M.J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl Jf Med 2005, 352(10): 987-96. (Pubitemid 40349501)
6. Stupp, R., Hegi, M.E., Mason, W.P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5): 459-66.
7. Westphal, M., Hilt, D.C., Bortey, E. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003, 5(2): 79-88. (Pubitemid 36422560)
8. Vredenburgh, J.J., Desjardins, A., Herndon, J.E. 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Reses 2007, 13(4): 1253-9. (Pubitemid 46424067)
9. Kreisl, T.N., Kim, L., Moore, K. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5): 740-5.
10. Humphrey, P.A., Wong, A.J., Vogelstein, B., Friedman, H.S., Werner, M.H., Bigner, D.D., Bigner, S.H. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 1988, 48(8): 2231-8.
11. Wikstrand, C.J., Hale, L.P., Batra, S.K. et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995, 55(14): 3140-8.
12. Wikstrand, C.J., McLendon, R.E., Friedman, A.H., Bigner, D.D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997, 57(18): 4130-40. (Pubitemid 27427708)
13. Humphrey, P.A., Wong, A.J., Vogelstein, B. et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990, 87(11): 4207-11.
14. Pelloski, C.E., Ballman, K.V., Furth, A.F. et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007, 25(16): 2288-94. (Pubitemid 46954657)
15. Heimberger, A.B., Hlatky, R., Suki, D. et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005, 11(4): 1462-6. (Pubitemid 40315227)
16. Boockvar, J.A., Kapitonov, D., Kapoor, G. et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 2003, 24(4): 1116-30. (Pubitemid 38091521)
17. Pedersen, M.W., Tkach, V., Pedersen, N., Berezin, V., Poulsen, H.S. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 2004, 108(5): 643-53. (Pubitemid 38076395)
18. Lammering, G., Hewit, T.H., Holmes, M. et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 2004, 10(19): 6732-43. (Pubitemid 39346571)
19. Montgomery, R.B., Guzman, J., O'Rourke, D.M., Stahl, W.L. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 2000, 275(23): 17358-63. (Pubitemid 30430771)
20. Nagane, M., Narita, Y., Mishima, K., Levitzki, A., Burgess, A.W., Cavenee, W.K., Huang, H.J. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 2001, 95(3): 472-9. (Pubitemid 32781500)
21. Inda, M.M., Bonavia, R., Mukasa, A. et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Deve 2010, 24(16): 1731-45.
22. Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., Rak, J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008, 10(5): 619-24. (Pubitemid 351627382)
23. Morgan, R.A., Johnson, L.A., Davis, J.L. et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012, 23(10): 1043-53.
24. Dirks, P.B. Cancer: Stem cells and brain tumours. Nature 2006, 444(7120): 687-8. (Pubitemid 44949580)
25. Sampson, J.H., Crotty, L.E., Lee, S. et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000, 97(13): 7503-8. (Pubitemid 30431493)
26. Heimberger, A.B., Archer, G.E., Crotty, L.E. et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effec- tive against murine intracerebral melanoma. Neurosurgery 2002, 50(1): 158-64; discussion 64-6. (Pubitemid 41672565)
27. Heimberger, A.B., Crotty, L.E., Archer, G.E. et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003, 9(11): 4247-54. (Pubitemid 37204046)
28. Sampson, J.H., Archer, G.E., Mitchell, D.A. et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009, 8(10): 2773-9.
29. Sampson, J.H., Heimberger, A.B., Archer, G.E. et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28(31): 4722-9.
30. Scott, A.M., Lee, F.T., Tebbutt, N. et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 2007, 104(10): 4071-6. (Pubitemid 47181580)
31. Hegi, M.E., Diserens, A.C., Gorlia, T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10): 997-1003. (Pubitemid 40349502)
32. Mehta, A.I., Persson, O., Herndon, J.E. et al. Immunotherapy for glioblastoma: The Devil Is in the Details Reply. J Clin Oncol 2011, 29(22): 3105-6.
33. Sampson, J.H., Aldape, K.D., Archer, G.E. et al. Greater chemotherapyinduced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology 2011, 13(3): 324-33.
34. Asavaroengchai, W., Kotera, Y., Mule, J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 2002, 99(2): 931-6. (Pubitemid 34106613)
35. Dummer, W., Niethammer, A.G., Baccala, R., Lawson, B.R., Wagner, N., Reisfeld, R.A., Theofilopoulos, A.N. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002, 110(2): 185-92. (Pubitemid 34787355)
36. Dudley, M.E., Wunderlich, J.R., Robbins, P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298(5594): 850-4. (Pubitemid 35231542)
37. Tanchot, C., Rosado, M.M., Agenes, F., Freitas, A.A., Rocha, B. Lymphocyte homeostasis. Semin Immunol 1997, 9(6): 331-7. (Pubitemid 28021490)
38. Lai, R.K., Recht, L.D., Reardon, D.A. et al., Long-term follow-up of ACT III: A phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma. Neuro-Oncol [16th Annu Sci Meet Soc Neuro-Oncol (Nov 17-21, Orange County) 2011] 2011, Abst IM-03.
39. Purev, E., Cai, D., Miller, E. et al. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 2004, 173(10): 6472-80. (Pubitemid 39487809)
40. Sok, J.C., Coppelli, F.M., Thomas, S.M. et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006, 12(17): 5064-73. (Pubitemid 44453332)
41. Wheeler, S.E., Suzuki, S., Thomas, S.M. et al. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010, 29(37): 5135-45.